Status Epilepticus

Meet the patient

The crash bleep goes at 03:14. A 54-year-old man with known epilepsy is on the floor of the ward, tonic-clonic. The nurse tells you he has been fitting for at least seven minutes, and he was meant to have his phenytoin at 22:00 but the dose was held for a forgotten reason. Capillary glucose is 5.1. IV access is in.^[1]

The clock has already crossed 5 minutes — you are now treating status epilepticus, not waiting to see if it stops. Two things will determine his outcome: that you give the full first dose of lorazepam now, and that you hunt the precipitant (the missed dose, an occult infection, a low sodium) from the first minute, not the tenth.^[4]

Why 5 minutes — the t1 and t2 rule

The ILAE 2015 operational definition frames SE around two time points that the examiner rewards precisely. t1 is the time beyond which a seizure must be treated as continuous — the brain's intrinsic seizure-terminating mechanisms have failed. t2 is the time beyond which long-term neuronal injury is accruing.^[1]

For generalised convulsive SE the values are t1 = 5 minutes and t2 = 30 minutes; for focal SE t1 is 10 minutes; for absence and myoclonic SE t1 is 10 to 15 minutes. The practical consequence is decisive: start treatment at 5 minutes, not 30. The window between five and thirty is when GABA-A receptors internalise, benzodiazepines lose effect, and the seizure becomes pharmacoresistant.^[1]

A second, older operational definition still appears in protocols: a continuous clinical or electrical seizure lasting at least 5 minutes, or two or more seizures without full recovery of consciousness between them. Both are correct and complementary. The staged protocol — benzodiazepine, then a second-line antiseizure drug, then anaesthesia — is among the most evidence-based treatments in neurology.^[2][4]

The three axes — semiology, response, cause

SE is classified along three independent axes because each changes the immediate management, the prognostic estimate, and the work-up.^[1]

By aetiology, SE uses the SAME framework — Structural, Autoimmune, Metabolic, Infectious, genetic, unknown — and splits into acute symptomatic (stroke, infection, metabolic, hypoxia — prognosis driven by the cause) versus remote or progressive, and known epilepsy (non-adherence, withdrawal) versus new-onset SE. The aetiological axis matters most at the bedside because an untreated precipitant will defeat any amount of benzodiazepine: the patient in status from profound hyponatraemia or an occult intracranial bleed keeps seizing until the sodium is corrected or the haematoma is evacuated.^[4]

The fourth distinction — convulsive versus non-convulsive — is the one most often missed. Subtle SE (minimal motor activity with ongoing electrographic seizure in a comatose patient, classically after prolonged GCSE) is a frequent cause of unexplained coma in intensive care.^[5]

Enlarge

How common, how lethal

SE has an annual incidence of roughly 10 to 40 per 100,000 (some studies report up to 60 to 65 per 100,000 in adults and over 150 in young children), with a bimodal age distribution — peaking in early childhood (under 5, often febrile or infectious) and again in the elderly (over 60, driven by stroke, dementia and metabolic causes).^[4][5]

Overall short-term case fatality is over 20 percent, rising to 30 to 40 percent in refractory SE and higher still in the elderly and in anoxic aetiology. About a third of patients presenting in SE have no prior history of epilepsy — a first seizure that does not stop can be the debut of a brain tumour, an intracranial bleed or an autoimmune encephalitis.^[4]

Why benzodiazepines fail the longer you wait

At its core, SE is a failure of the brain's intrinsic seizure-terminating mechanisms, with a progressive, self-reinforcing shift from inhibitory (GABAergic) dominance to excitatory (glutamatergic) dominance. Early on, GABA-A receptors are abundant on the neuronal surface and benzodiazepines work well. As the seizure continues, two molecular events produce time-dependent pharmacoresistance — the phenomenon that governs the whole protocol.^[4][5]

• GABA-A receptors are internalised — trafficked off the synaptic membrane into clathrin-coated vesicles, so the surface density of the benzodiazepine target falls, inhibition wanes, and a dose that worked at 5 minutes may fail at 30.
• NMDA and AMPA glutamate receptors are recruited and upregulated to the synapse, so excitation rises, calcium floods the neuron, and the seizure becomes self-sustaining.^[1]

Enlarge

The downstream excitotoxic cascade — sustained NMDA-mediated calcium influx, mitochondrial dysfunction, oxidative stress and ATP depletion — drives neuronal necrosis and apoptosis. The hippocampus (CA1 and CA3 pyramidal cells) is the most vulnerable region, and the long-term consequence of prolonged SE is mesial temporal sclerosis, lasting cognitive impairment, and a substantially higher risk of future epilepsy. This is the molecular reason t2 sits at 30 minutes.^[5]

The systemic consequences of prolonged convulsive SE compound the brain injury and become life-threatening in their own right: hypoxia and aspiration, lactic acidosis from sustained muscle activity, hyperpyrexia, rhabdomyolysis (myoglobinuria, acute kidney injury, compartment syndrome), an autonomic surge, hyperkalaemia, disseminated intravascular coagulation, neurogenic pulmonary oedema, and cardiac ischaemia or arrhythmia from catecholamine excess. A patient can die of SE without the brain being the immediate cause of death.^[4]

The precipitants — find the cause from minute one

The commonest precipitants, in roughly descending order: antiseizure-drug non-adherence or withdrawal (the single commonest cause in known epilepsy and the most readily reversible), CNS infection (meningitis, encephalitis — and in India neurocysticercosis and CNS tuberculosis are over-represented), metabolic disturbance (hyponatraemia, hypoglycaemia, hypocalcaemia, hepatic and renal failure), stroke (ischaemic or haemorrhagic), hypoxic-ischaemic encephalopathy after cardiac arrest, alcohol withdrawal, brain tumour (primary or metastatic), head trauma, and drug toxicity (tricyclics, isoniazid, theophylline, tramadol, cocaine).^[4]

At the bedside — ABCDE plus the clock and glucose

Immediate assessment is ABCDE plus timing. Secure the airway with an adjunct or recovery position, give high-flow oxygen, obtain IV access, time the seizure precisely from onset, and check capillary glucose at once — hypoglycaemia is rapidly reversible and is the classic mimic and precipitant that must never be missed.^[2][4]

Draw bloods for glucose, U&E, LFT, calcium, magnesium, FBC, CRP, blood gas and lactate, AED levels, toxicology (including alcohol), and beta-hCG in every woman of childbearing age — an eclamptic seizure changes the entire first-line drug.^[2]

Two bedside rules decide many exam answers. First, give IV thiamine before any glucose in the alcohol-misusing or malnourished patient — providing glucose before thiamine can cause or exacerbate Wernicke encephalopathy, and it is generally recommended to administer thiamine prior to glucose when thiamine deficiency is suspected. Second, a patient who has stopped overtly convulsing but remains comatose after GCSE is in non-convulsive SE until proven otherwise — request an urgent EEG, do not assume the seizure has ended.^[10][5]

Investigations — glucose first, EEG when the brain won't wake

The immediate bedside test is capillary glucose; the emergency blood panel is venous glucose, U&E, LFT, calcium, magnesium, FBC, CRP, blood gas and lactate, toxicology, AED levels and beta-hCG. An ECG is done in every patient — both to exclude a long-QT arrhythmia or cardiac syncope masquerading as seizures, and to monitor the cardiac effects of fosphenytoin or phenytoin (PR prolongation, QRS widening, hypotension).^[4]

Neuroimaging, once the patient is stabilised and the seizure controlled, begins with CT brain acutely to exclude haemorrhage, mass effect, large stroke or abscess. MRI brain follows later for aetiology. Imaging is deferred until the airway and seizure are controlled — never delay treatment for a scan, and never send an unstable or actively convulsing patient to the scanner.^[4]

Lumbar puncture is indicated when CNS infection is suspected and is deferred until raised ICP or a mass lesion is excluded by CT and the patient is stable, with coagulation checked. Send CSF for cells, protein, glucose (paired with plasma), Gram stain, culture, viral PCR (especially HSV) and, where the picture fits, autoimmune or paraneoplastic antibodies (anti-NMDA-receptor, LGI1, GAD). Start empiric antimicrobial therapy (ceftriaxone plus aciclovir, plus IV amoxicillin or ampicillin if Listeria risk factors are present — age over 50, immunocompromise, pregnancy; add vancomycin only where cephalosporin-resistant pneumococcus is a concern) before imaging if the suspicion of meningitis or encephalitis is high.^[4]

EEG is mandatory in four situations: whenever NCSE is suspected (the comatose or confused post-convulsion patient), in all refractory and super-refractory SE, to titrate the anaesthetic infusion to burst-suppression, and in any patient who fails to recover consciousness after a convulsion. The electrographic signature is rhythmic spikes or spike-wave discharges that evolve in frequency, morphology and field. Continuous EEG (cEEG) is the monitoring standard for any comatose patient after GCSE.^[4][5]

Enlarge

The four-stage protocol — reproduce the drug, dose, route, timing

This is the single highest-yield piece of reproducing knowledge in the topic. The times below are the AES 2016 framework; many UK and Indian protocols compress stages 1 and 2 and use a 0–5, 5–10, 10–30, over-30 sequence — both are acceptable if the doses are correct.^[2][4]

Intubate and ventilate when GCS is under 8, airway reflexes are lost, respiratory failure develops from aspiration, or refractory SE mandates anaesthesia.^[4]

Stage 2 — the emergent benzodiazepine

Give IV lorazepam 4 mg as an initial therapy dose; if seizures continue, a second identical dose is given (the classic trial regimen was one or two doses of lorazepam 4 mg, or diazepam 10 mg as the alternative). IM midazolam is the route of choice when IV access cannot be quickly secured — the RAMPART trial showed IM midazolam at least as safe and effective as IV lorazepam in the pre-hospital setting, and superior when IV access is not established.^[7][2][3]

Stage 3 — the second-line agent (post-ESETT)

If still seizing after an adequate benzodiazepine (= established SE), give one of: IV levetiracetam, IV fosphenytoin or IV sodium valproate. The ESETT trial (2019) established that these three agents are equally effective and safe: each led to cessation of status epilepticus with improved alertness by 60 minutes in roughly half of patients (levetiracetam 47%), with similar incidences of adverse events.^[6]

Stage 4 — refractory and super-refractory

Intubate (using a rapid-sequence induction that avoids a long-acting paralytic obscuring the neurological exam) and transfer to ICU. Start an anaesthetic infusion titrated with continuous EEG to burst-suppression or complete seizure abolition for 24 to 48 hours before a slow wean. Refractory SE = ongoing despite benzodiazepine plus one adequate second-line agent. Super-refractory SE = ongoing or recurring over 24 hours after onset of anaesthetic infusion.^[4]

Paediatric weight-based doses follow the same staged framework. In the paediatric emergency-department trial, children received IV lorazepam 0.1 mg/kg or IV diazepam 0.2 mg/kg, with half the dose repeated at 5 minutes if necessary. The second-line agents — levetiracetam, fosphenytoin and valproate — were studied in children as well as adults in ESETT. When IV access is unavailable in the pre-hospital setting, IM midazolam is at least as safe and effective as IV lorazepam.^[8][6][3]

Specific scenarios — the drug that changes

Non-convulsive SE. Suspect it in any comatose or confused patient after a seizure, and confirm with EEG. Treat with an IV benzodiazepine trial or a non-sedating antiseizure drug (levetiracetam, lacosamide) rather than immediate anaesthesia — the goal is to abort the seizure without obscuring the neurological examination. Over-sedation converts an assessable patient into a ventilated one and hides the very findings needed to guide management.^[5]

Refractory and super-refractory SE. Once SE persists into stage 4, intubate, use an anaesthetic infusion (propofol, midazolam or thiopentone) with continuous EEG, and titrate to burst-suppression for 24 to 48 hours before a slow wean. If the cause is autoimmune (anti-NMDA-receptor encephalitis, anti-LGI1, anti-GAD), add immunotherapy early — IV methylprednisolone, IV immunoglobulin and plasma exchange — because untreated autoimmune SE is among the most refractory forms and responds to immunosuppression, not to escalating anaesthesia alone. The ketogenic diet is a recognised rescue therapy, and ketamine (an NMDA antagonist) infusion is increasingly used as a third- or fourth-line agent.^[4]

Eclamptic SE. The drug of choice is IV magnesium sulphate — the Cochrane review states plainly that magnesium sulphate is the drug of choice for the prevention and treatment of eclampsia — alongside obstetric planning for delivery, the definitive treatment. Magnesium, not a benzodiazepine-first approach, is first-line for eclamptic seizures; alternative regimens and routes exist, but no single regimen has proved superior in reducing maternal mortality or major morbidity.^[11]

Alcohol-withdrawal SE. Give a benzodiazepine (IV lorazepam or diazepam) to terminate the seizure and IV thiamine before any glucose — providing glucose before thiamine can cause or exacerbate Wernicke encephalopathy, and thiamine should be given prior to glucose whenever deficiency is suspected — then continue benzodiazepine therapy to prevent further withdrawal seizures.^[2][10]

Post-anoxic SE after cardiac arrest. Managed within targeted temperature management (32 to 36 degrees Celsius for 24 hours); the prognosis is guarded, and continuous EEG is essential to detect myoclonic or non-convulsive SE, which may be the only sign of ongoing injury.^[4]

How status patients come to harm (the preventable list)

• Under-dosing the first benzodiazepine — a timid lorazepam dose that fails and is labelled "refractory"^[5]
• Missing NCSE in a comatose patient because no EEG was requested^[5]
• Not treating a reversible precipitant (hypoglycaemia, hyponatraemia, infection) while escalating the pharmacological ladder^[4]
• Misdiagnosing PNES as refractory SE and escalating a non-epileptic patient to anaesthesia — the EEG would have been flat^[5]
• Sending an unstable or actively convulsing patient to the scanner before the airway and seizure are controlled^[4]
• Forgetting the eclampsia diagnosis in a postpartum woman and reaching for a benzodiazepine instead of magnesium^[4]
• Missing isoniazid overdose in a patient with refractory SE and not giving pyridoxine (vitamin B6)^[4]

Prognosis — aetiology is the determinant

Mortality is over 20 percent overall, rising to 30 to 40 percent in refractory SE and higher in the elderly and anoxic aetiology. It is worst with an anoxic cause (post-cardiac-arrest myoclonic SE, where mortality can exceed 70 percent) and best with alcohol-withdrawal or AED non-adherence (often under 5 percent when the cause is reversed). Aetiology is the single most important determinant of outcome, ahead of duration and age.^[4]

The Status Epilepticus Severity Score (STESS) stratifies outcome from four variables: worst level of consciousness (0 awake to 3 coma), worst seizure type (0 simple partial or absence to 3 non-convulsive or subtle under anaesthesia), age (0 under 65, 1 over 65), and prior seizures (0 yes — protective, 1 no). Range 0 to 6: STESS 0 to 3 predicts good outcome; 4 to 6 predicts poor — but it is never used to withhold treatment in real time.^[1]

Disposition. Refractory SE, intubated patients, those with GCS under 8, and the haemodynamically unstable need ICU. A patient whose SE is controlled early with a clearly reversible precipitant (a missed phenytoin dose) may be managed on a monitored ward after observation. Before discharge, optimise chronic AED therapy and adherence — the risk of recurrent SE and new-onset epilepsy stays elevated for months to years.^[4]

The named trials — what changed practice

The guideline and trial base in one breath: the ILAE 2015 operational definition (Trinka) introduced the t1/t2 time points — the basis for treating GCSE at 5 minutes and recognising injury risk at 30.^[1] The AES 2016 evidence-based guideline (Glauser) formalised the staged protocol: IV lorazepam first-line, IM midazolam if no IV, levetiracetam, fosphenytoin or valproate as second-line.^[2] RAMPART (2012) established IM midazolam for the pre-hospital setting.^[3] ESETT (2019) established equivalence of the three second-line agents and ended the default use of phenytoin.^[6]

The role of continuous EEG as the monitoring standard — in all refractory SE, all super-refractory SE, and in any comatose patient after GCSE to exclude NCSE — is now a near-universal guideline recommendation across regions.^[4]

The mantra, and the protocol in one breath

The mantra: 5 minutes, 4 milligrams, then escalate — and never stop hunting the precipitant.^[1]

Ward-round test — three stems, thirty seconds each